Alpheus Medical Opens Enrollment in New Clinical Trial for Butterfly Glioblastoma
The study will evaluate PoMA™ therapy, Alpheus' drug-led, tumor-selective treatment approach, in patients with butterfly glioblastoma, a particularly aggressive form of GBM involving both cerebral hemispheres. The trial design requires PoMA therapy prior to standard chemoradiation...
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


